Most neurostimulation devices can be manually adjusted by users and their caregivers to customize treatments for chronic pain, epilepsy, stroke recovery and more, but an implant newly approved by the ...
Next Generation Senza ® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif., Oct. 12, ...
REDWOOD CITY, Calif., Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...
HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real ...
(RTTNews) - Medical device company Nevro Corp. (NVRO) Monday said new data from a study showed the health economic benefits of its 10 kHz spinal cord stimulation (SCS) therapy for the treatment of ...
REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...
HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* ...
HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback